APLS
Price
$19.43
Change
+$0.33 (+1.73%)
Updated
Jun 6, 04:10 PM (EDT)
Capitalization
2.4B
66 days until earnings call
DNLI
Price
$14.79
Change
+$0.57 (+4.01%)
Updated
Jun 6, 04:15 PM (EDT)
Capitalization
2.07B
55 days until earnings call
Interact to see
Advertisement

APLS vs DNLI

Header iconAPLS vs DNLI Comparison
Open Charts APLS vs DNLIBanner chart's image
Apellis Pharmaceuticals
Price$19.43
Change+$0.33 (+1.73%)
Volume$2.05K
Capitalization2.4B
Denali Therapeutics
Price$14.79
Change+$0.57 (+4.01%)
Volume$100
Capitalization2.07B
APLS vs DNLI Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. DNLI commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (APLS: $19.10 vs. DNLI: $14.23)
Brand notoriety: APLS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 82% vs. DNLI: 134%
Market capitalization -- APLS: $2.4B vs. DNLI: $2.07B
APLS [@Biotechnology] is valued at $2.4B. DNLI’s [@Biotechnology] market capitalization is $2.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 4 bearish.
  • DNLI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, APLS is a better buy in the short-term than DNLI.

Price Growth

APLS (@Biotechnology) experienced а +9.71% price change this week, while DNLI (@Biotechnology) price change was +5.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.4B) has a higher market cap than DNLI($2.07B). DNLI YTD gains are higher at: -30.201 vs. APLS (-40.144). APLS has higher annual earnings (EBITDA): -176.08M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. APLS (358M). DNLI has less debt than APLS: DNLI (48.6M) vs APLS (470M). APLS has higher revenues than DNLI: APLS (776M) vs DNLI (0).
APLSDNLIAPLS / DNLI
Capitalization2.4B2.07B116%
EBITDA-176.08M-505.16M35%
Gain YTD-40.144-30.201133%
P/E RatioN/AN/A-
Revenue776M0-
Total Cash358M818M44%
Total Debt470M48.6M967%
FUNDAMENTALS RATINGS
APLS vs DNLI: Fundamental Ratings
APLS
DNLI
OUTLOOK RATING
1..100
5659
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9540
PRICE GROWTH RATING
1..100
8986
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (72) in the Medical Distributors industry is in the same range as DNLI (93) in the Biotechnology industry. This means that APLS’s stock grew similarly to DNLI’s over the last 12 months.

APLS's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as DNLI (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for APLS (95) in the Medical Distributors industry. This means that DNLI’s stock grew somewhat faster than APLS’s over the last 12 months.

DNLI's Price Growth Rating (86) in the Biotechnology industry is in the same range as APLS (89) in the Medical Distributors industry. This means that DNLI’s stock grew similarly to APLS’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that DNLI’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSDNLI
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 18 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NARCX62.93N/A
N/A
Voya Multi-Manager International Sm Cp C
PIBAX17.80N/A
N/A
PGIM Balanced A
CDDRX34.77N/A
N/A
Columbia Dividend Income Inst2
JGSMX21.00N/A
N/A
JPMorgan Small Cap Growth R6
SJVIX28.58N/A
N/A
Steward Large Cap Value I

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+3.19%
ROIV - APLS
46%
Loosely correlated
-0.18%
BPMC - APLS
45%
Loosely correlated
-0.14%
EYPT - APLS
43%
Loosely correlated
+0.61%
DNLI - APLS
43%
Loosely correlated
-1.35%
BEAM - APLS
42%
Loosely correlated
-0.87%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.35%
NRIX - DNLI
56%
Loosely correlated
+2.80%
BEAM - DNLI
55%
Loosely correlated
-0.87%
ARWR - DNLI
54%
Loosely correlated
-1.73%
RGNX - DNLI
53%
Loosely correlated
-17.36%
DAWN - DNLI
52%
Loosely correlated
+0.29%
More